Advancing T Cell Engagers for Solid Tumors Corporate Presentation March 2026 Executive Summary Forward Looking Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company's current views about future events and is subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company's actual activities or results to differ significantly from those expressed in any forw ...

Harnessing the Power of Gamma -Delta T Cells March 2, 2026 IN8bio, Inc. | IN8bio, Inc. | +1 646.600.6GDT (6438) +1 646.600.6GDT (6438) | | infinf o@IN8bio.com o@IN8bio.com | | www.IN8bio.com www.IN8bio.com Disclaimer The material in this presentation regarding IN8bio, Inc . ("we," "us" or the "Company") is for informational purposes only . This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , that involve substantial risks and unc ...

Core Insights - Werewolf Therapeutics is advancing its pipeline with a focus on INDUKINE programs and the INDUCER T cell engager platform, seeking strategic partnerships for further development of WTX-124 and WTX-330 [1][2] Pipeline Updates - WTX-124 has shown a 30% overall response rate as a monotherapy in advanced or metastatic cutaneous melanoma patients, with a favorable tolerability profile [4] - WTX-330 demonstrated additional antitumor activity and a highly favorable tolerability profile in its Phase 1b/2 trial, building on previous Phase 1 data [4][6] - Upcoming data updates for WTX-124 and WTX-330 are expected in the first half of 2026, with the completion of the Phase 1/1b clinical trial for WTX-124 anticipated [7] Clinical Data Highlights - WTX-124 achieved a 21% objective response rate in heavily pretreated advanced melanoma patients, with a 30% response rate in those who previously responded to immunotherapy [5] - Tumor regression was observed in approximately 33% of tumors across various cancer types treated with WTX-124 [5] - WTX-330's initial data indicated a confirmed partial response in metastatic gall bladder cancer, with a 45% reduction in tumor target lesions [12] Development Strategy - The company plans to file IND applications for two INDUCER candidates, WTX-1011 and WTX-2022, by mid-2027, targeting STEAP1 and CDH6-expressing cancers respectively [4][8] - Werewolf's INDUCER molecules aim to improve therapeutic index and reduce off-tumor toxicity, leveraging a proprietary masking approach and novel linker technology [8] Company Overview - Werewolf Therapeutics is focused on developing therapeutics that stimulate the immune system for cancer treatment, utilizing its PREDATOR platform to create conditionally activated INDUKINE and INDUCER molecules [9]